NCT02844309 2026-02-11
BDH-WM02
Institute of Hematology & Blood Diseases Hospital, China
Phase 4 Completed
Clinical Trials
7 trialsNCT01779167 2018-07-11
THRiL for WM
Weill Medical College of Cornell University
Phase 2 Terminated
NCT03335098 2017-11-07
BOMB-THROW
Seoul National University Hospital
Phase 2 Unknown
NCT00723658 2015-03-06
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT00142116 2014-06-02
Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00052416 2013-06-26
Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00083707 2010-07-05
Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia
University of Arkansas
Phase 2 Completed